Agilent Technologies, Inc. (A) AI Stock Analysis

Agilent Technologies, Inc. delivers tailored solutions across life sciences, diagnostics, and applied chemistry. Its Life Sciences and Applied Markets segment supplies advanced instrumentation including liquid chromatography mass spectrometry, gas chromatography systems, molecular spectroscopy tools, laboratory automation, and analytics software. The Diagnostics and Genomics segment provides genetic analysis tools, next-generation sequencing platforms, DNA mutation detection arrays, specialized reagents, and interpretation software. The Agilent CrossLab segment complements these divisions with consumables, instrument supplies, startup support, operational training, compliance services, and software as a service.

Agilent's revenue expanded from $6.32B in FY2021 to $6.95B in FY2025, delivering a 5-year revenue CAGR of 5.4% from FY2020 to FY2025. Annual growth saw fluctuations, dropping 0.2% in FY2023 and 4.7% in FY2024 before rebounding 6.7% in FY2025. Gross margin was 52.4% in FY2025, while operating margin stood at 21.3% and net income reached $1.30B. Diluted EPS grew from $4.34 in FY2021 to $5.58 in FY2025. Over the trailing twelve months, revenue was $7.37B, operating margin rose to 25.6%, and profit margin reached 19.5%. In the quarter ended July 31, 2026, quarterly revenue grew 8.1% and earnings rose 8.5%.

As of July 31, 2026, Agilent held $1.76B in cash and short-term investments alongside $3.95B in total debt, resulting in net debt of $2.19B. Total assets were $13.97B and shareholders' equity was $7.36B, reflecting a current ratio of 2.05 and a debt-to-equity ratio of 0.54. In FY2025, operating cash flow was $1.56B and free cash flow was $1.15B. Capital allocation during FY2025 included $407.0M in capital expenditures, $425.0M in share buybacks, and $282.0M in dividends paid, contributing to a 5-year share count reduction of 7.2%.

At a share price of $172.97, Agilent carries a market capitalization of $48.77B and an enterprise value of $48.80B. The stock trades at a trailing P/E of 34.1x and a forward P/E of 23.9x, both above the median of its S&P 500 Healthcare peers (27.2x and 16.5x, respectively). Its EV/EBITDA of 24.0x also exceeds the peer median of 15.0x. Over the past year, the stock returned 23.5%, outperforming the 16.8% return of the S&P 500, but its 5-year return of 17.0% trailed the index benchmark's 83.0%.

Agilent pays a forward annual dividend of $1.02 per share, yielding 0.59% with a payout ratio of 16.8%. Dividends are distributed quarterly and have been paid for 15 consecutive years, with an annualized 5-year dividend growth rate of 6.6%. The company's last ex-dividend date was October 6, 2026.

Wall Street coverage consists of 11 Strong Buy, 4 Buy, and 7 Hold ratings, with no Sell recommendations. The mean price target is $181.05, representing an upside of 4.7% over the last close of $172.97. For the fiscal year ending October 31, 2026, consensus estimates project EPS of $6.20 on revenue of $7.50B. For the subsequent fiscal year, 22 analysts expect EPS of $6.75 and revenue of $7.98B. The company beat EPS estimates in 3 of the last 4 quarters, with the next earnings release scheduled for November 23, 2026.

This page is an AI-written research summary of Agilent Technologies, Inc. (A). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: A income statement, A balance sheet, A key metrics, A analyst forecast, A chart. See the A stock overview for the latest quote and news.